Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia: Phase II Randomized Clinical Trial

NCT06748105 is registered in ClinicalTrials.gov with Lauro Fabián Amador Medina as lead sponsor.

NCT NCT06748105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06748105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia: Phase II Randomized Clinical Trial
Lead sponsor
Lauro Fabián Amador Medina
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2024
Completion date
December 1, 2025
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dapagliflozin (forxiga), glucocorticoid, hyperglycaemia